Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cidara Thera (CDTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 128,136
  • Shares Outstanding, K 16,860
  • Annual Sales, $ 0 K
  • Annual Income, $ -48,170 K
  • 36-Month Beta 1.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.96

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.40 +18.75%
on 08/23/17
7.75 -1.94%
on 09/22/17
+0.85 (+12.59%)
since 08/22/17
3-Month
5.60 +35.71%
on 08/16/17
8.15 -6.75%
on 07/27/17
+0.70 (+10.14%)
since 06/22/17
52-Week
5.60 +35.71%
on 08/16/17
12.64 -39.87%
on 09/23/16
-4.67 (-38.06%)
since 09/22/16

Most Recent Stories

More News
Cidara Therapeutics to Present at Two Upcoming Conferences

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer...

CDTX : 7.60 (+6.29%)
Cidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance Congress

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., the company's president and chief...

CDTX : 7.60 (+6.29%)
Antimicrobials Working Group Member Companies Announce Partnership and Exclusive Pricing Program

The Antimicrobials Working Group (AWG) is pleased to announce that two of its member companies, T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products...

TTOO : 4.29 (+3.13%)
CDTX : 7.60 (+6.29%)
T2 Biosystems and Cidara Therapeutics Announce Partnership for Commercial Placement of T2Dx Instruments to Support CD101 Drug Trials

T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, and Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company...

TTOO : 4.29 (+3.13%)
CDTX : 7.60 (+6.29%)
T2 Biosystems and Aridis Pharmaceuticals, Inc. Join Antimicrobials Working Group

The Antimicrobials Working Group (AWG) announced today the addition of two new members to their group of 12 companies with the mission to combat drug resistant infections and spur life-saving innovations....

TTOO : 4.29 (+3.13%)
CDTX : 7.60 (+6.29%)
Cidara Provides Corporate Update and Reports Second Quarter 2017 Financial Results

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended June 30, 2017 and...

CDTX : 7.60 (+6.29%)
T2 Biosystems Joins Antimicrobials Working Group as First Diagnostic Member

T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today that it will join the Antimicrobials Working Group...

TTOO : 4.29 (+3.13%)
CDTX : 7.60 (+6.29%)
CDTX: Insiders vs. Shorts

The most recent short interest data was recently released for the 06/15/2017 settlement date, and Cidara Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 8.57 "days to...

CDTX : 7.60 (+6.29%)
Cidara Therapeutics Joins SAFE-BioPharma Association

SAFE-BioPharma Association, the non-profit coalition of biopharmaceutical companies that developed and manages the global SAFE-BioPharma(R) digital identity management and digital...

CDTX : 7.60 (+6.29%)
Cidara Therapeutics Announces Presentations at ASM Microbe 2017 and the 22nd Congress of the European Hematology Association

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies of its novel...

CDTX : 7.60 (+6.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company...

See More

Support & Resistance

2nd Resistance Point 8.15
1st Resistance Point 7.88
Last Price 7.60
1st Support Level 7.20
2nd Support Level 6.79

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.